1. Scrip
  2. >>Business

Lundbeck Pursues Brintellix Infringement Charges In India

 
• By Anju Ghangurde

Lundbeck seeks to ward off Alembic and Hetero over alleged patent infringing activity pertaining to its depression therapy vortioxetine in India. The product is seen as one of the key drivers of growth in 2021 for the Danish company, which has settled infringement proceedings with over half a dozen generic opponents so far in the US.

SC1911_Patent Infringement_417199606_1200.jpg
Lundbeck Takes On Alleged Infringers Of Vortioxetine Patent In India • Source: Shutterstock

H. Lundbeck A/S is pursuing legal proceedings in India against Alembic Pharmaceuticals Limited and Hetero Drugs Ltd. for allegedly infringing its patent pertaining to the antidepressant Brintellix (vortioxetine), a product that is a key revenue contributor globally for the Danish firm and one that has also seen generic opponents lining up in the US.

Separate cases against both Alembic and Hetero in the Delhi High Court allege that the Indian companies have infringed Lundbeck’s Indian patent IN 227963, pertaining to vortioxetine, which was granted in 2009

More from Business

More from Scrip

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.